Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This observational study is conducted in Europe. The objective of this retrospective observational cohort analysis is to assess the changes of glycaemic control and quality of care in those Type 2 diabetic patients who were previously treated with Mixtard® insulins after 6 months of their switch to analog premix insulin NovoMix® 30 therapy.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin aspart, insulin aspart protamine drug combination 30:70; Insulin, Globin Zinc; Insulin, Isophane; Insulin, pork; isophane insulin, pork drug combination 30:70

Criteria

Inclusion Criteria:

• Subjects diagnosed with type 2 diabetes previously treated with BHI for at least 12 months

• Analogue premix administration for the last 6 months

Exclusion Criteria:

• Known or suspected allergy to insulin aspart

• Newly diagnosed diabetes